Summary We investigated the reasons for referral of older Australians aged 70 years and older to dual energy X-ray absorptiometry (DXA). The most common clinical indication was being aged 70 years and older, followed by monitoring for fracture or low bone mineral density (BMD). Compared to males, females were twice as likely to have osteoporotic BMD. Purpose/Introduction Little is known about reasons for the referral of older Australians to dual energy X-ray absorptiometry (DXA) for bone mineral density (BMD) measurements. Thus, we aimed to document the reasons for referral to DXA in Australian men and women aged 70 years and older and investigate any differences between the sexes.
Introduction
Osteoporosis is a systemic skeletal disease characterised by low bone mineral density (BMD) and micro-architectural deterioration of bone tissue, with a consequent increase in susceptibility to fracture [1, 2] . Fragility fractures at the spine, hip, forearm and proximal humerus are a major public health problem for both sexes, and current estimates of annual direct and indirect costs are in excess of $2.75 billion [3] . Approximately 4.7 million Australians have osteoporosis or osteopenia (low BMD), and this figure is estimated to reach 6.2 million by the year 2022 [3] . Although osteoporosis increases the risk of fracture, it is suggested that the population burden arises from individuals with osteopenia, not osteoporosis [1, 4] . Despite osteoporosis prevalence being greater for women than men [3, 5] , it is men that experience higher rates of osteoporosis-related mortality [6] and are more likely to remain untreated for the disease [7, 8] .
Dual energy x-ray absorptiometry (DXA) is used to measure BMD and acts as one of the key strategies to inform decision-making processes regarding low BMD and antifracture therapies [9, 10] . We recently reported there was minimal increase in the utilisation of DXA by Australian men and women aged 70 years and older, after changes to national health policy introduced by Medicare Australia in 2007 [11] . We found that although the proportion of men undergoing DXA doubled from 2003 to 2010, the proportion tripled for women; importantly, the overall utilisation of DXA in this age group remained low [11] . In order to make a conceptual advance in our understanding of physician referral behaviour and patient initiation of testing, it is imperative from a treatment and public health standpoint that we understand the clinical indications for which older Australians are referred to DXA. Thus, we aimed to document the reasons for referral to DXA in Australian men and women aged 70 years and older and investigate any differences between the sexes.
Methods

Study region
Data were derived from the electronic records of the Geelong Bone Densitometry Service, Barwon Health, Victoria, Australia. The Geelong Bone Densitometry Service is the major DXA service provider for the Barwon Statistical Division (BSD), south-eastern Australia, and operates two DXA machines to serve a regional population of approximately 250,000 of whom 30,252 (57.2 % female) were aged 70 years or over at the 2006 Australian Census [12] . This study was approved by the Barwon Health Human Research Ethics Committee.
Study population
All men and women aged ≥70 years referred to DXA for osteoporosis-related reasons (non-research purposes) during 2003-2010 were identified from the administrative patient records database of the Geelong Bone Densitometry Service by use of the Medicare Australia item numbers that were associated with the referral.
Patients were included for analyses if they underwent a DXA test during the period 2003-2010, resided in the BSD at time of DXA and were aged ≥70 years. Subsequent attendances at DXA were not included in analyses, and individuals that were scanned for research purposes were excluded. Of the total 15,032 patient records identified from the database as aged ≥70 years, records were excluded for the following reasons: missing values for the lowest BMD T Score (n=7), missing data regarding reason for referral (n=547), patient duplicates (n=7) and not a resident of the BSD (n=97). BMD values measured at the femoral neck and spine (L2-L4) were ascertained for each patient, and using the T score provided by the DXA manufacturers (Lunar DPX-L [Lunar Corporation, Madison, WI, USA] or GE Lunar Prodigy [GE Lunar, Madison, WI, USA] after the DPX-L was outmoded) were classified as being within the normal range (−1.0 or more SD below the young reference mean), osteopenic range (−1.0 to −2.5 SD below the young reference mean) or osteoporotic range (<−2.5 SD below the young reference mean) at either the femoral neck or spine.
Medicare Australia item numbers
The Medicare item numbers of interest were 12306 (minimal trauma fracture or monitoring of low BMD as detected by a previous scan), 12312 (prolonged glucocorticoid therapy, excess glucocorticoid secretion or hypogonadism in both sexes), 12315 (secondary osteoporotic conditions such as chronic liver or kidney disease, primary hyperparathyroidism, malabsorption disorders, rheumatoid arthritis or excess thyroxine), 12321 (changes in class of drug therapy) and 12323 (persons aged ≥70 years).
Statistical analysis
Sex differences in demographic characteristics, BMD (categories, and as a continuous measure) and clinical indications for DXA referral were examined using the chi-square test or Kruskal-Wallis for categorical and non-parametric data, respectively. The likelihood of having BMD in the osteoporotic range vs. the normal or osteopenic range was examined using binary logistic analyses, with adjustment made for age (as a continuous variable) and sex; the referent categories in the models were male sex, the age group of 70-74 years and the clinical indication for referral of being a person aged ≥70 years (Medicare Item number 12323). Results are presented as odds ratios (ORs), 95 % confidence intervals (95%CI) and p values. Statistical analyses were performed using Minitab (Version 16; Minitab, State College, PA, USA), and significance was set at p<0.05.
Results
Characteristics of the study population are presented in Table 1 (78.5 % female). Of the 5438 eligible patient records, fractures were observed in all 5-year age stratum: 70-75 years (n= 1815), 75-80 years (n=1724), 80-85 years (n=1259), 85-90 years (n=546), 90-95 years (n=86) and ≥95 years (n=8). No age differences were observed between the sexes (p= 0.32). The most common reason for referral to DXA was being aged 70 years or older (64.6 %), with a greater proportion of women than men referred for this reason (65.9 vs. 60.0 %, p<0.001). The opposite was seen for the clinical indication of prolonged glucocorticoid therapy, for which men were more likely referred than women (14.4 vs. 6.6 %, p<0.001). A non-significant sex differences in referral reasons was also observed for patients that were being monitored for changes in class of drug therapy; however, the number of referrals in this category was small (0.5 % for men vs. 1.1 % for women, p=0.08). No sex differences were observed for those referred to DXA due to minimal trauma fracture or low BMD. Women had a lower BMD T score compared to men (−2.3±1.1 vs. −1.6±1.4 SD below the adult sex-specific reference ranges, respectively). A greater proportion of men than women had BMD in the normal range (30.2 % for men vs. 10.9 % for women, p<0.001), whereas sex differences in the opposite direction were seen for BMD in the osteopenic range (47.7 % for women vs. 44.3 % for men, p=0.04) and in the osteoporotic range (41.4 % for women vs. 25.5 % for men, p<0.001). Table 2 presents the binary logistic regression associations between clinical indications for referral to DXA and the odds of having BMD in the osteoporotic range, adjusted for age and sex. Compared to individuals referred to DXA, because they were aged 70 years or older (referent group), individuals that were referred because of minimal trauma fracture or for the purposes of monitoring low BMD were more likely to have BMD in the osteoporotic range (OR 1.46, 95%CI 1.28-1.67) . We also observed that individuals referred to DXA because of change in class of drug therapy were more likely to have BMD in the osteoporotic range (OR 2.12, 95%CI 1.19-3.76) compared to those that were referred because they were aged 70 years or older (referent group). Advancing age showed a proportional relationship with osteoporotic BMD; the strength of association ranged from OR 1.34 (95%CI 1.16-1.54) for the 75-79-year age group to OR 5.63 (95%CI 1.13-28.03) for those aged 95 years or older. Women were more than twice as likely to have BMD in the osteoporotic range compared to men (women OR 2.25, 95%CI 1.95-2.61). Table 3 presents the median BMD T scores for each of the clinical indications for DXA referral, stratified by sex. Sex differences were observed for BMD for each of the clinical Significant p values are in boldface † BMD T score (femoral neck) was categorised as being within the normal range (−1.0 or more SD below the young reference mean), osteopenic range (−1.0 to −2.5 SD) or osteoporotic range (<−2.5 SD 
Discussion
In this referred population of older Australians, the most common clinical indication for undergoing DXA was being aged 70 years or older, followed by monitoring for a fracture or low BMD. We report a proportional association between advancing age and the likelihood of having a BMD in the osteoporotic range. We also report that, compared to males, females were twice as likely to have osteoporotic BMD. The following discussion pertains to each of the referral reasons. Ageing is one of the major factors that influence the risk of osteoporosis [3, 5] ; being aged 70 years or older was the most common reason for referral. In our referred population, we observed no age differences between the sexes at the time of DXA. As might be expected, advanced age was strongly associated with having BMD in the osteoporotic range. Undergoing a DXA when aged 70 years or older is a likely consequence of the nationwide push to increase the utilisation of DXA testing in older Australians, introduced in 2007, to avoid or delay minimal trauma fractures [11, 13] . However, we have previously reported from this same study region that 1.8 % of men and 6.3 % of women aged 70 years or older were referred to DXA in 2010 [11] ; proportions that are unlikely to impact on reducing fracture risk in Australia.
A referral due to fracture or low BMD was the second most common reason for referral for older adults of both sexes. As has previously been observed in younger adults [14] , there were no sex differences in the proportion of referrals for this category. However, women had lower BMD T scores compared to men; in addition, the BMD T score of women fell into the osteoporotic range, whereas for men, their BMD T score indicated osteopenia. These findings may be influenced by the definitive reason for referral, whether it was for fracture or monitoring of BMD; however, the period of our data ascertainment did not enable us to distinguish between the two, as we were unable to determine whether patients had a scan prior to 2003. We can confirm, however, that we included only the initial scan and excluded subsequent scans, and we can thereby speculate that the majority of the DXA referrals in this population were related to minimal trauma fractures.
Compared to women, a higher proportion of men were referred for DXA because of glucocorticoid exposure. Glucocorticoid use increases the likelihood for the development of secondary osteoporosis; a meta-analysis showed that the frequency of glucocorticoid-induced osteoporosis is as high as 50 % of individuals that used glucocorticoids for 6 months or longer [15] .
No sex differences were observed in the proportion of men and women referred to DXA because of changes in drug therapy. Individuals who undergo DXA for the purposes of monitoring drug therapy would by nature already have a diagnosis of osteoporosis. It is interesting that, in this referral category, men made up only 11.5 % of all older adults tested, suggesting that men continue to remain undertreated for this disease.
Our study has strength. Prior to this study there were little comprehensive data identifying the reasons older Australians undergo DXA testing. Our analyses spanned an 8-year period and encompassed all adults aged 70 years and older that attended the one major DXA service provider for an entire geographical district. Our study also has some limitations. The period of our data extraction did not unable us to clarify whether patients had a DXA prior to 2003. Our observed sex differences in the proportion of referrals could be influenced by competing mortality. Given that we are unable to account for the possibility that some older adults may have undergone a DXA test at a small private service provider that also services the BSD region, and even though we speculate our data ascertainment includes the majority of DXA tests, this limited our ability to investigate the referral rates per head of population in this region. We make the assumption that the Medicare Australia Item numbers recorded in the electronic database of the Geelong Bone Densitometry Service were precise, although acknowledge that administrative data records such as these may be influenced by misclassification due to human error. Finally, whilst we acknowledge that the presence of abnormalities at the spine may artefactually influence BMD at this site [16] ; x-rays of the spine were not comprehensively available.
We observed the most common reason for referral, regardless of sex, was being aged 70 years or older. However, given that referred women were twice as likely as men to have BMD in the osteoporosis range, this suggests that even more women may need to be referred to DXA.
